Nonprofit Funding Platform Heroe5 Launches The Good Society, Embracing Web3 Approach to the Sustainable Financial Benefit for Charities
14.9.2022 15:49:00 EEST | Business Wire | Press release
Nonprofit funding platform Heroe5™ announced today the creation of The Good Society™ to address the growing need for sustainable funding platforms for charitable organizations. The Good Society becomes the first project focused on Web3 solutions to raise awareness and support global causes working to positively impact our communities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220728005376/en/
“The Good Society is a vital next step in the evolution of the fundraising industry: a Web3 platform to create art impact experiences,” said Sebastien Heimann, founding member and CEO of Heroe5 and The Good Society. “As the world moves to Web3, charities need more fundraising tools to stay ahead of the curve and embrace new ways to engage potential donors. The Good Society will provide those innovations, allowing them to raise critical funding and awareness for vital causes while feeding the public’s growing interest in digital collectables.”
With each drop 1800 digital collectibles designed by acclaimed artists will be released each month supporting a broad range of nonprofits working to improve the environment, wildlife, human rights, and our collective health and wellbeing. A percentage of these art impact experiences will grant token carriers access to unique events in perpetuity.
Artist Nate Mohler created “Out of Sight | Out of Mind” for The Good Society’s first program, which benefits Lonely Whale, No More Plastic, and Oceanic Global. The digital collectables, scaled to 3840 x 3840 pixels, 26 seconds in length and layered with “white sound,” emphasize the risk to fragile ocean ecosystems from the human-caused plastic pollution in urban environments and highlight how much there is left to learn. Three of the many cities featured in “Out of Sight | Out of Mind” include London, Los Angeles, and Paris.
“No matter where you live, the oceans provide the oxygen you breathe, nurture the food you eat, and regulate the temperature of the air. Without a healthy ocean we’d have a very different experience on land,” said Mohler. “This series is not of the oceans but of major cities, which emit 60% of all carbon emissions and make up less than 1% of the Earth’s surface. Similar to my ongoing series ‘Painted Cities’ there are three unique styles intended to bring a more ephemeral and dreamlike memory of the city.”
One of every 15 of the digital collectibles will also provide owners access to experiences that are provided by the benefiting organizations and artists for each drop. Some of the experiences tied to this premier release include:
- Two front row seats at Paris Fashion Week
- Two passes to Oceanic Global’s annual gathering for ocean conservation
- An annual artist critique call with Nate Mohler
- Invitations to Lonely Whale's annual leadership virtual town hall which discuss its programs and preview its impact report
Digital collectors will easily be able to purchase the artwork with a credit card or Tez, cryptocurrency of the Tezos blockchain, when they are minted on August 12 at 2pm ET. Once sold out, more than $1M (US) in new funding will be available to the benefiting organizations and, as the digital collectables are resold, the organizations will receive residual payments from each transaction.
Quotes from Benefiting Organizations
“Lonely Whale’s goal is simple - to keep plastic out of the ocean. We want to thank each person who buys one of Nate Mohler’s striking NFTs through The Good Society, which will support the creative development and market adoption of alternatives to thin-film plastic and directly address the nearly 180 billion polybags used every year by the fashion industry.” – Harry Bernstein, Chief Creative Officer, Lonely Whale
“Plastic pollution has become one of the biggest environmental scourges of our time. Microplastics are everywhere: in the deep ocean, in Antarctic ice, even falling rain over mountains and cities. Plastic pollution not only pollutes our planet; it pollutes our blood. We must act and the time is now. We are grateful to The Good Society for entrusting No More Plastic Foundation with this generous funding. With it, we will continue our work to end the cycle of plastics and microplastics flowing into our ocean.” – Rosalie Mann, Founder & President, No More Plastic
“We live on a blue planet. The ocean covers 70% of the surface of the earth and produces every other breath we take. Our well-being is intrinsically tied to the ocean. Thanks to The Good Society and their innovative fundraising platform and model – and to artiste extraordinaire Nate Mohler – Oceanic Global will be able to keep empowering individuals, communities, and industries to create positive change for a thriving ocean.” – Lea d'Auriol, Founder & Executive Director, Oceanic Global
About The Good Society
The Good Society harnesses the power of non fungible tokens to fund global initiatives. Designed by acclaimed digital artists, every month a new NFT will drop that raises awareness and secures funding for nonprofits working to improve the environment, human rights, and our collective health and wellbeing. Led by Sebastien Heimann, the Co-founder & CEO of fundraising platform Heroe5, The Good Society leverages the uniqueness of Web3 to deliver a powerful and recurring source of funding. For more information visit thegoodsociety.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220728005376/en/
Contact information
Press
Famous Last Words PR
Carolyn Zweifel: carolyn@flwpr.com
Fred Shank: fred@flwpr.com
Jen Peros: jen@flwpr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
